

Ipsen in oncology

Key figures¹



100+ countries where Ipsen medicines are marketed



Invested **€445.3m in R&D** representing about **14.7%** of sales



~5,000 employees around the world are committed to tackling areas of high unmet medical needs to improve the quality of life of patients and caregivers


1. 2022 URD

Want to know more? Visit [Ipsen.com](https://www.ipsen.com) to see our commitment to patients in action

At Ipsen we work with patients, for patients

Together, we deliver better access to information and innovation to improve lives

WE WORK WITH **250** PATIENT ORGANIZATIONS* WORLDWIDE ACROSS OUR **THREE** THERAPEUTIC AREAS**



*At 5th May 2023

**Some Patient Organizations (POs) cover more than one therapy area

ONCOLOGY CASE STUDY

Patient Support Program

Neuroendocrine Tumors (NETs) & Acromegaly



In response to NHS capacity pressures and to reduce patient's travel to hospitals for ongoing, regular treatment, Ipsen UK developed their Homecare service – now known as the Ipsen HomeZonePLUS service



Since **April 2017**, Ipsen UK have partnered with Logistics **AND** Nursing provider companies to ensure patients can receive their medication at their homes and benefit from nursing support if it is required, with the aim of achieving Self/Other administration.



73 = Number of NHS Centres signed to PSP in 2024
3,350 = Patients receiving their medication at home, each month
1,325 = Patients receiving nurse support
98.4% = Average Patient Satisfaction Rating



Ipsen UK are helping more patients to Self/Other administration, increasing their independence and freedom; setting the standards for Homecare patients, adding value and reassurance for clinicians

IPSEN'S COMMITMENT TO PATIENT CENTRICITY



We start the **dialogue** as early as possible with patients when developing new medicines

We **collaborate** with patient communities to develop solutions together that deliver long-term impact



We **transform** Ipsen science to make a meaningful difference to patients' lives

WOULD YOU LIKE TO KNOW MORE?

We would love to hear from you

Email us at:

patientcentricity@ipsen.com

Or find out more at:

www.ipsen.com/patients

www.ipsenmedicalinformation.com



NOT ALL HOOFBEATS ARE HORSES...

THINK ZEBRA!

Neuroendocrine tumors (NETs) commonly arise within the gastrointestinal tract and pancreas. They are thought of as rare 'ZEBRAS' of the gastroenterology and cancer world, meaning patients are commonly misdiagnosed and often face long diagnostic delays, with a mean time to a correct diagnosis of ~5 years.¹

However, NETs are not as rare as often thought; they are more prevalent than any other gastrointestinal cancer except colorectal adenocarcinoma.¹⁻⁴

Download the guide
and **THINK ZEBRA**
in your everyday
clinical practice



5 YEARS

Is the mean time to a correct diagnosis of a NET¹

(n=2,359 NET patients)

44%

of NET patients are initially misdiagnosed¹

(n=2359)



1. Kolarova T, et al. Presented at IASGO 2021, based on INCA SCAN results. 2. Dureja S, et al. J. Neuroendocrinol. 2023; 35(6):e13310. 3. Khan M.S, et al. Frontline Gastroenterol. 2020; 13(1):50-56. 4. Eads J.R, et al. Pancreas 2020;49(9):1123-1130.

WHEN SHOULD YOU THINK ZEBRA?

Symptom ^{1,2}	Intestinal NET		Pancreatic NET					
	Functioning (carcinoid syndrome)	Non-functioning	Functioning					Non-functioning
			Gastrinoma	Insulinoma	Glucagonoma	VIPoma	Somatostatinoma	
Flushing	✓							
Diarrhea	✓		✓		✓		✓	
Abdominal pain	✓							
Valvular heart disease	✓							
Wheezing	✓							
Pellagra-like skin lesions	✓							
Zollinger-Ellison syndrome Severe peptic ulceration and diarrhea, or diarrhea alone			✓					
Confusion				✓				
Sweating				✓				
Dizziness				✓				
Weakness				✓				
Unconsciousness				✓				
Necrolytic migratory erythema					✓			
Diabetes mellitus					✓		✓	
Weight loss					✓		✓	
Stomatitis					✓			
Watery diarrhea with marked hypokalaemia						✓		
Cholelithiasis							✓	
Steatorrhoea							✓	
Large abdominal masses		✓						
Bleeding from the GI tract		✓						
Intestinal obstruction	✓	✓						
Abdominal discomfort (due to growing tumor)	✓	✓						
Pain	✓							✓
Liver enlargement								✓
Jaundice (occasionally)								✓

60–90%
of pancreatic NETs are
non-functioning tumors³

Functioning NETs
produce symptoms due to
the excessive production
of hormones¹



NET=neuroendocrine tumor; VIP=vasoactive intestinal peptide.

1. Ramage JK, et al. Gut. 2012;61(1):6–32; 2. Oberg K. Annals of Oncology. 2004;15(Supplement 4):iv293–iv298; 3. Falconi M, et al. Neuroendocrinology. 2016;103(2):153–171.